about
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fateAn intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitorCortactin is a component of clathrin-coated pits and participates in receptor-mediated endocytosisActin and Arf1-dependent recruitment of a cortactin-dynamin complex to the Golgi regulates post-Golgi transportRapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells.Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 inductionLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics.In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy.Get off my back! Rapid receptor internalization through circular dorsal ruffles.Testis-specific murine centrin, Cetn1: genomic characterization and evidence for retroposition of a gene encoding a centrosome protein.Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics.Caveolin-1 interacts directly with dynamin-2.Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalizationCell death when the SAC is out of commission
P50
Q24648997-BA89B5A4-5295-4CB3-B8F4-E34F75ABD4C1Q28476280-72A8CBB0-0F54-4D79-ABAD-213706D272CAQ28572352-1F004704-3A7A-42D5-A1F2-8EACF56B3209Q28581970-63A1CE6C-3968-4A2F-AB36-93274E47DB32Q30503448-953CDBEE-DB67-43FE-A812-72998B3E92D7Q30505355-C71DC1F9-FE04-4A39-9A80-1773413A02B6Q30665952-742B7508-501D-4184-9DD9-74AF408B485EQ34446806-72318B45-13BA-4839-AFF6-89B4469520BDQ36026406-54B2641B-5809-48DC-A73C-2EBCB116C9A9Q36084123-A6E8433D-E6F0-49CE-ABB1-696934705B98Q36673646-4B2296D3-F366-45F0-9CDA-830B4C82C6DBQ38320667-733D7A20-CF54-4DAE-B73A-8529C2FD08F6Q38806892-FB6E2E44-5A2D-4D67-AEFD-CBAE254E444FQ39516435-AC53ED84-071A-46B6-B9F6-DCDB6BFF4C6AQ40438684-F8B5DC1A-CBA8-43F8-8D2C-5DE95EBA6708Q42128896-50751BB3-2311-43A9-9BB8-1E7E2F8B00D6Q46616195-A5149C06-0559-438A-AB60-D4818D3AFA7BQ83057528-4CBBA2D5-9D39-4BB2-9490-D66536B26BE4Q84432732-0A98B73B-94D5-4178-B762-F81247C64ADC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
James D Orth
@ast
James D Orth
@en
James D Orth
@es
James D Orth
@nl
type
label
James D Orth
@ast
James D Orth
@en
James D Orth
@es
James D Orth
@nl
prefLabel
James D Orth
@ast
James D Orth
@en
James D Orth
@es
James D Orth
@nl
P106
P1153
7007052206
P31
P496
0000-0002-8559-6186